IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?
This article compares two Invesco biotech ETFs, IBBQ and PBE, highlighting their different investment strategies. IBBQ offers broad diversification across 251 companies with a lower expense ratio, while PBE employs a concentrated, quant-driven approach with 31 holdings and a higher dividend yield. The analysis helps investors determine which ETF aligns better with their investment goals, considering factors like expense ratios, diversification, and dividend yields.
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
AstraZeneca has suffered a major setback in the PD-1 bispecific market with a Phase III non-small cell lung cancer (NSCLC) trial failure for volrustomig. This development is a blow to the company's aspirations of leading in PD-1-based bispecific antibodies for solid tumors in Western markets. Despite this, AstraZeneca is continuing volrustomig trials in various other cancers including cervical cancer, renal cell carcinoma, and mesothelioma, as well as other NSCLC patient segments.
Is Amgen (AMGN) Fully Priced As Analysts Lift Targets After Second Quarter Results?
Following strong second-quarter results, Argus has raised its price target for Amgen (AMGN) to $460 from $375, maintaining a Buy rating. Despite this, Simply Wall St's most popular narrative suggests Amgen is overvalued by about 20.5% at its current share price of US$433.73, citing concerns about manufacturing capacity for new drugs. Conversely, Simply Wall St's DCF model indicates Amgen might be undervalued, estimating a future cash flow value of $691.35.
Bank of New York Mellon Corp Sells 97,857 Shares of Amgen Inc. $AMGN
Bank of New York Mellon Corp reduced its stake in Amgen Inc. by 2.6% during the second quarter, selling 97,857 shares, though it still holds a significant position of over 3.69 million shares. Several other institutional investors adjusted their holdings in Amgen, with some increasing and others initiating stakes. Analysts have issued varied ratings and price targets for Amgen, resulting in a current consensus "Hold" rating with an average price target of $380.43.
AssuredPartners Investment Advisors LLC Grows Stock Holdings in Amgen Inc. $AMGN
AssuredPartners Investment Advisors LLC significantly increased its stake in Amgen Inc. by 191.2% in Q2, bringing its total holdings to 10,651 shares valued at $3.86 million. This comes as Amgen exceeded analyst expectations for its quarterly earnings and revenue, with revenue rising 9.5% year-over-year. Despite mixed analyst sentiment, several firms have raised their price targets for Amgen, which also declared a quarterly dividend of $2.52 per share.
B. Metzler seel. Sohn & Co. AG Cuts Holdings in Amgen Inc. $AMGN
B. Metzler seel. Sohn & Co. AG reduced its stake in Amgen Inc. by 10.4% in the second quarter, selling 4,539 shares and retaining 39,041 shares valued at approximately $14.1 million. This reduction comes amidst mixed analyst sentiment, with a consensus "Hold" rating despite several upgrades and a strong Q2 earnings report where Amgen surpassed analyst estimates with EPS of $6.29 and revenue of $10.05 billion. The company also declared a quarterly dividend of $2.52 per share.
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk
Alvotech's stock rose 7% to US$4.27 after reaffirming its full-year revenue guidance of US$650m to US$700m and adjusted EBITDA of US$180m to US$220m, despite a 31% year-on-year dip in first-half revenue. The company, a biosimilar specialist, is still operating at a loss, but regulatory progress and new capital have fueled a bullish outlook. However, bears point to the reliance on milestone and partner flows and low product margins as ongoing risks.
Incyte: Cheaper, Growing Faster, And The Market Keeps Paying Up For Amgen
This article compares Amgen (AMGN) and Incyte (INCY), highlighting Amgen's higher valuation despite Incyte's faster revenue growth and lower price-to-operating-income ratio. It analyzes Amgen's premium as the cost of diversification and a promising late-stage pipeline, particularly its obesity asset MariTide. The piece concludes by framing the investment choice as a balance between Amgen's potential pipeline and Incyte's proven commercial momentum and cheaper valuation.
Amgen Named to The Wall Street Journal's Inaugural 2026 Best Companies for the Future List
Amgen has been recognized on The Wall Street Journal's inaugural 2026 Best Companies for the Future list, ranking 39th with an overall score of 63.5 out of 100. The company was evaluated on AI readiness, innovation, talent readiness, financial fitness, resilience, and agility, notably achieving the second-highest resilience score. This acknowledgment highlights Amgen's ongoing commitment to patient care and its preparedness for future challenges in the evolving business landscape.
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth
The biotechnology industry is experiencing a powerful rally, fueled by groundbreaking innovation, the surging obesity drug market, and increased mergers and acquisitions. This growth has led to key biotech indices significantly outperforming the Nasdaq 100. Investors can capitalize on this bullish trend by investing in diversified biotech ETFs, which mitigate the risks associated with individual stock picks while still offering exposure to the sector's robust growth.
Eupraxia Pharmaceuticals Market Sentiment
This article provides an overview of market sentiment for Eupraxia Pharmaceuticals (EPRX), including analyst consensus, short interest, options flow, and insider activity. It highlights that 6 analysts have a "Buy" consensus with an average price target of $16, indicating a significant upside. The article also lists recent analyst actions with their ratings and price target changes.
ETFs Investing in Amgen Inc. Stocks
This article lists various ETFs that include Amgen Inc. (AMG) stocks in their portfolios. It provides a detailed table with each ETF's market value, weight of Amgen stock, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify funds that offer diversified exposure to Amgen Inc. at potentially lower risk.
Amgen exits TScan TCR discovery collaboration tied to over USD 500m in milestones
Amgen has terminated its research collaboration and license agreement with TScan Therapeutics, effectively removing over $500 million in potential milestone payments for TScan. The agreement, originally signed in May 2023, focused on using TScan's platform to identify antigens for Crohn's disease, with Amgen holding exclusive development rights. TScan will retain all licenses, and its primary focus remains its oncology-focused TCR-T pipeline, which recently dosed its first patient in a Phase III trial.
Can RedHill Biopharma (NASDAQ:RDHL) Show Commercial Progress Today?
RedHill Biopharma (NASDAQ:RDHL) is scheduled to report financial results today, placing scrutiny on its commercial execution, development programs, funding, and balance sheet. The article emphasizes that company-specific operational evidence regarding clinical and commercial progress, patient access, and cash discipline is more crucial than broad market assumptions. Readers should focus on qualitative signals like customer decisions, inventory movement, and alignment of capacity with demand to assess the company's real progress.
Wealthfront Advisers LLC Sells 6,410 Shares of Amgen Inc. $AMGN
Wealthfront Advisers LLC decreased its stake in Amgen Inc. by 7.1% in the second quarter, selling 6,410 shares but still retaining 84,152 shares valued at approximately $30.5 million. Amgen reported strong Q2 earnings and revenue, exceeding consensus estimates, and declared a quarterly dividend of $2.52 per share. Despite the stock trading near its 52-week high, analyst sentiment remains mixed with an average "Hold" rating and a price target below current trading levels.
ETFs Investing in Amgen Inc. Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Amgen Inc. (AMG) stocks, sorted by market value. It details various ETFs, including their market value, weight of Amgen stock, issuer, management style, focus, expense ratio, assets under management (AUM), current price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify ETFs with Amgen holdings, emphasizing the benefits of ETFs for accessibility, opportunities, and lower risk in stock investing.
Main Street Financial Solutions LLC Takes $1.66 Million Position in Amgen Inc. $AMGN
Main Street Financial Solutions LLC has acquired a new stake in Amgen Inc., purchasing 4,589 shares valued at approximately $1.66 million. Amgen reported strong Q2 earnings, beating analyst estimates with $6.29 EPS and $10.05 billion in revenue, and declared a quarterly dividend of $2.52 per share. Institutional investors collectively own 76.5% of Amgen's stock, while analysts maintain a "Hold" rating with an average price target of $379.36.
Amgen Inc. $AMGN Shares Sold by Danske Bank A S
Danske Bank A S reduced its holdings in Amgen Inc. by 6.8% in the second quarter, selling 29,273 shares, though other institutional investors like Norges Bank and BlackRock Inc. significantly increased their stakes. The article also details recent analyst ratings, Amgen's strong financial performance including a raised dividend, and insider share sales by SVP Nancy A. Grygiel and SVP Rachna Khosla.
Amgen Inc. $AMGN Shares Sold by Great Lakes Advisors LLC
Great Lakes Advisors LLC decreased its holdings in Amgen Inc. by 15.6% in the second quarter, selling 19,901 shares but still retaining 107,992 shares valued at $39.1 million. Despite this sale, institutional investors collectively own 76.5% of Amgen's stock. The company exceeded analyst expectations with its recent earnings report, posting $6.29 EPS and $10.05 billion in revenue, and has a consensus "Hold" rating from analysts with a target price below its current trading value.
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
Merck has significantly outperformed its peers, Amgen and Pfizer, in 2026, with a 44% year-to-date gain, largely due to its oncology franchise and new product launches, rather than a GLP-1 obesity drug. Amgen secured second place with a 35% gain, while Pfizer lagged with 14% but offered a compelling 6.3% dividend yield. The article notes that Merck's success came despite the sector's focus on obesity drugs this year.
Amgen Inc Stock (AMGN) Moved Up by 3.19% on Aug 19: What Investors Need To Know
Amgen Inc (AMGN) saw a 3.19% increase in its stock price on August 19, driven by a positive analyst upgrade from Argus and strong second-quarter financial results that exceeded Wall Street expectations. The company also benefited from a sector-wide rally in healthcare equities and investor focus on its late-stage clinical pipeline, particularly its novel obesity asset, MariTide. Technical indicators show a MACD buy signal and RSI buy condition, though the Williams %R suggests an overbought condition.
Amgen abandoning $500M+ Crohn’s collab won't derail TScan’s strategy
Amgen has terminated its collaboration with TScan Therapeutics for a Crohn's disease project, which had potential milestones of over $500 million. Despite this setback, TScan states that its pipeline strategy, primarily focused on blood cancers and solid tumors, remains unaffected as their role was limited to target discovery. This decision follows a strategic review by Amgen and minimal financial impact is expected for TScan.
The Smartest Dividend ETF to Buy With $500 Right Now
The Schwab U.S. Dividend Equity ETF (SCHD) is highlighted as a smart investment for consistent, higher-yielding dividends, outperforming the S&P 500 this year. It tracks the Dow Jones U.S. Dividend 100 index, holding high-quality companies like Coca-Cola and Abbott Laboratories, which are Dividend Kings. A $500 investment in SCHD, yielding 3.1%, would buy approximately 14.48 shares.
Protalix (PLX) Q2 2026 Earnings Call Transcript
Protalix BioTherapeutics reported strong financial results for Q2 2026, driven by Elfabrio sales and a significant milestone payment. The company reiterated its full-year 2026 revenue guidance and maintained a debt-free balance sheet with $40.7 million in cash. Protalix is advancing its PRX-115 Phase 2 RELEASE study for uncontrolled gout, with top-line results expected in late 2027, and secured a multiyear patent extension for Elfabrio in the U.S.
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline
Sarepta Therapeutics reported strong Q2 2026 financial results, including $328.7 million in net product revenue and both GAAP and non-GAAP operating income, driven by PMO and ELEVIDYS sales. The company also announced the appointment of Michael Severino as its new CEO, who will lead Sarepta's continued advancement of its rare disease pipeline, with key data readouts for DM1 and FSHD expected in H2 2026 and a new Huntington's disease program initiated. Despite a year-over-year revenue decrease attributed to an updated ELEVIDYS label and a missed milestone payment, Sarepta narrowed its 2026 revenue guidance to $1.2 billion to $1.3 billion and ended Q2 with a robust cash position of approximately $945 million.
Amgen Inc. $AMGN Shares Purchased by Simplicity Wealth LLC
Simplicity Wealth LLC significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, more than doubling its position to 10,539 shares valued at $3.8 million. This comes as Amgen reported strong quarterly results with revenue up 9.5% and EPS exceeding analyst estimates, alongside a declared quarterly dividend of $2.52 per share. Despite positive financial performance and several institutional buys, the consensus analyst rating for Amgen remains "Hold" with an average price target of $375.93.
Trust Co. of Vermont Purchases New Position in Amgen Inc. $AMGN
Trust Co. of Vermont recently acquired a new stake in Amgen Inc., purchasing 22,744 shares valued at approximately $8.24 million during the second quarter. This move comes as other institutional investors have also adjusted their positions in the medical research company. Amgen has reported strong financial performance, with quarterly revenue up 9.5% year-over-year and diluted earnings per share beating analyst expectations.
ETFs Investing in Amgen Inc. Stocks
This article lists various ETFs that invest in Amgen Inc. stocks, providing details such as market value, weight of Amgen in the ETF, issuer, management style, expense ratio, and AUM. The information aims to help investors find accessible and lower-risk opportunities by diversifying through ETFs holding Amgen shares.
Hikari Power Ltd Sells 22,090 Shares of Amgen Inc. $AMGN
Hikari Power Ltd has significantly reduced its stake in Amgen Inc. by selling 22,090 shares, decreasing its holdings by 71.3% during the second quarter. Following this transaction, the firm now owns 8,900 shares of Amgen, valued at $3.22 million. Other institutional investors have also adjusted their positions in Amgen, while analysts maintain a consensus "Hold" rating with an average target price of $375.93.
Amgen Inc. $AMGN Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.
Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Amgen Inc. by 7.0% in the second quarter, now owning 0.27% of the company's stock valued at $535.36 million. This acquisition is part of a broader trend of institutional investors and hedge funds adjusting their positions in AMGN. Analyst ratings for Amgen are predominantly "Hold" with a consensus price target of $375.93, while the company recently reported strong financial results and announced a quarterly dividend.
Deutsche Bank AG Buys 99,946 Shares of Amgen Inc. $AMGN
Deutsche Bank AG increased its stake in Amgen Inc. by 4.4% in the second quarter, purchasing an additional 99,946 shares. Other institutional investors like Norges Bank, Capital World Investors, and State Street Corp also made significant investments in Amgen, with hedge funds and institutional investors owning 76.50% of the stock. Wall Street analysts have issued various ratings for Amgen, with a consensus "Hold" rating and an average price target of $375.93.
AMG National Trust Bank Has $3.57 Million Position in Amgen Inc. $AMGN
AMG National Trust Bank reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 24.4% in the second quarter, now holding shares worth $3.57 million. Despite this, other institutional investors have increased their positions. Amgen recently reported strong quarterly earnings, exceeding analyst expectations, and announced a quarterly dividend of $2.52 per share.
BlackRock Inc. Has $17.87 Billion Stock Holdings in Amgen Inc. $AMGN
BlackRock Inc. significantly increased its stake in Amgen Inc. during the second quarter, now holding 49,362,016 shares valued at $17.87 billion, representing 9.15% of the company. Other institutional investors also adjusted their positions in Amgen, which recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend. Analyst ratings are mixed, with a consensus "Hold" rating and an average target price of $375.93, while insider sales have also been noted.
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth potential. However, the valuation hinges on successful execution for INGREZZA and CRENESSITY, with risks from pricing pressure and higher SG&A.
TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing
Amgen has decided to terminate its research collaboration and license agreement with TScan Therapeutics. This information was disclosed via an SEC filing. The full details of this termination can be found in the mentioned SEC filing.
Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Amgen Inc. stock gained 1.41% on Tuesday, closing at $425.28, despite a generally negative trading session where the S&P 500 and Dow Jones Industrial Average both fell. Despite its daily gains, Amgen underperformed compared to its competitors. This marks the second consecutive day of gains for the stock.
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration
Amgen has terminated its Research Collaboration and License Agreement with TScan Therapeutics (TCRX), impacting over $500 million in potential milestone payments and future royalties related to Crohn's disease research. TScan had previously received a $30 million upfront payment, and will not incur any early termination penalties. The termination will become effective on November 10, 2026, and TScan will wind down its research activities, though royalties could still be earned if Amgen continues to exploit product candidates developed under the collaboration.
The Bull Case For Amgen (AMGN) Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why
Amgen Inc. recently reported strong second-quarter 2026 results, with revenues of US$10,054 million and net income of US$2,375 million, leading to raised full-year 2026 guidance. The company now expects total revenue between US$38.20 billion and US$39.40 billion, and GAAP EPS of US$15.80 to US$17.08. This positive update strengthens Amgen's investment narrative, supporting its long-term growth driven by both existing drugs and a developing pipeline, despite ongoing risks from biosimilar competition and pricing pressures.
Amgen (NASDAQ:AMGN) Reaches New 1-Year High on Analyst Upgrade
Amgen (NASDAQ:AMGN) shares recently hit a new 52-week high after Cantor Fitzgerald raised its price target, although the firm maintained a neutral rating. The company's latest quarterly results surpassed expectations, with EPS of $6.29 and revenue up 9.5% year-over-year. Despite the stock's recent rally, the overall analyst consensus remains "Hold," with an average target price below current trading levels, and company insiders have sold over $2.5 million in shares in the last 90 days.
Cantor Fitzgerald raises Amgen stock price target on core portfolio strength
Cantor Fitzgerald has increased its price target for Amgen (NASDAQ: AMGN) shares from $350 to $400, while maintaining a Neutral rating, due to strong performance expectations for its core portfolio products like Repatha, Evenity, and Uplizna. The firm also revised its fiscal 2026 revenue forecast to $39.2 billion, exceeding the company's guidance, and raised EPS estimates for 2026-2028. This follows Amgen's robust second-quarter results, which surpassed Wall Street expectations and prompted similar price target adjustments from other firms.
Amgen stock hits all-time high at 422.49 USD
Amgen Inc. (AMGN) stock has reached an all-time high of $422.49, currently trading at $424.54, reflecting a 47.6% surge over the past year. InvestingPro analysis suggests the stock remains undervalued with a Fair Value of $443.20, indicating further growth potential. This milestone follows strong second-quarter earnings that surpassed Wall Street expectations, leading analysts to raise price targets for the biotechnology company.
Amgen (NASDAQ:AMGN) Given New $352.00 Price Target at Mizuho
Mizuho has increased its price target for Amgen (NASDAQ:AMGN) to $352.00 from $303.00, while maintaining a "neutral" rating, which implies a potential 16% downside from the current stock price. Despite this, Amgen recently reported strong quarterly earnings of $6.29 EPS and revenue of $10.05 billion, both exceeding analyst estimates. Insiders have sold approximately $2.54 million worth of shares over the past 90 days, though institutional investors hold a significant 76.50% of the company's stock.
AMGN Maintains by Cantor Fitzgerald -- Price Target Raised to $4
Cantor Fitzgerald maintained a "Neutral" rating on Amgen (AMGN) while raising its price target from $350 to $400, signaling cautious optimism. Despite a strong GF Score™ of 83/100, Amgen is currently considered overvalued, trading at a 14.9% premium to its intrinsic value. Insider selling activity also suggests a need for caution among investors.
Jessica Vargas Appointed Vice President of Human Resources at Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. has appointed Jessica Vargas as Vice President of Human Resources, bringing significant experience in HR business partnering and talent acquisition. Vargas will be responsible for the company’s people strategy, organizational development, and culture, supporting Fennec's mission to improve patient outcomes. Her extensive background includes roles at Amgen, Horizon, Graphic Packaging International, and Fenwal, Inc., spanning approximately 18 years in HR.
Wilkinson Global Asset Management LLC Lowers Holdings in Amgen Inc. $AMGN
Wilkinson Global Asset Management LLC significantly reduced its stake in Amgen Inc. by 26.9% in the second quarter, selling over 50,000 shares but still retaining a substantial holding valued at approximately $49.4 million. Despite this reduction and mixed analyst sentiment, Amgen reported strong quarterly earnings, beating expectations with an EPS of $6.29 and revenue up 9.5% year over year, and also declared a quarterly dividend of $2.52 per share. Institutional investors and hedge funds collectively own 76.5% of Amgen's stock, though there have been notable insider sales recently.
Russell Investments Group Ltd. Sells 37,910 Shares of Amgen Inc. $AMGN
Russell Investments Group Ltd. reduced its stake in Amgen Inc. by 10.7% in the second quarter, selling 37,910 shares and now owning 316,051 shares valued at $114.32 million. Several other hedge funds adjusted their positions in Amgen, while company insiders, including SVP Rachna Khosla and SVP Nancy A. Grygiel, sold a combined total of 6,222 shares worth over $2.5 million. Amgen also announced a quarterly dividend of $2.52 per share and received updated price targets and ratings from various analysts.
Amgen Inc. $AMGN Shares Acquired by Kinsale Capital Group Inc.
Kinsale Capital Group Inc. increased its stake in Amgen Inc. by 12.2% in the second quarter, now owning 42,075 shares valued at $15.24 million. Other institutional investors like Vanguard Group Inc. and State Street Corp also significantly increased their holdings in Amgen. The article also details recent insider stock sales, Amgen's financial performance, dividend announcement, and updated analyst ratings.
Mitsubishi UFJ Trust & Banking Corp Purchases 5,903 Shares of Amgen Inc. $AMGN
Mitsubishi UFJ Trust & Banking Corp increased its stake in Amgen Inc. by 2.0% in the second quarter, now owning 304,371 shares valued at $110,219,000. Several other hedge funds also adjusted their holdings in Amgen. Additionally, recent insider transactions show senior vice presidents Nancy A. Grygiel and Rachna Khosla selling shares, while the company reported strong quarterly earnings and declared a quarterly dividend of $2.52 per share.
Kelleher Financial Advisors Buys 2,580 Shares of Amgen Inc. $AMGN
Kelleher Financial Advisors increased its stake in Amgen Inc. by 96.4% in the second quarter, purchasing an additional 2,580 shares to own a total of 5,256 shares valued at $1.9 million. This move is part of a broader trend of institutional investment in Amgen, with several other firms also increasing their holdings. Analysts currently have a "Hold" rating on Amgen with a consensus price target of $372.39, while the company recently announced a quarterly dividend of $2.52 per share.
Global Retirement Partners LLC Takes $8.88 Million Position in Amgen Inc. $AMGN
Global Retirement Partners LLC has acquired a new position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, purchasing 24,522 shares valued at approximately $8.88 million. Other institutional investors also adjusted their holdings in Amgen, with the company reporting strong quarterly earnings that surpassed analyst estimates. Amgen also announced a quarterly dividend of $2.52 per share.
